latest update:
[TrialBase DB]

trial summary · NCT07389980

Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial

Trial record from the TrialBase DB dataset, status RECRUITING, condition Polypoidal Choroidal Vasculopathy, sponsored by Yeungnam University College of Medicine. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07389980phase PHASE3enrollment 50start 2026-12-24

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.

Source record: https://clinicaltrials.gov/study/NCT07389980

Facts

registry idNCT07389980
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE3
study typeINTERVENTIONAL
lead conditionPolypoidal Choroidal Vasculopathy
sponsorYeungnam University College of Medicine
sponsor classOTHER
enrollment50
start date2026-12-24
primary completion2028-11
completion2028-12
results postednot reported

Conditions

  • Polypoidal Choroidal Vasculopathy
  • Polypoidal Choroidal Vasculopathy (PCV)

Interventions

  • aflibercept 8 mg

Countries

  • South Korea

Intervention types: DRUG

Work with this record